The business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma co...

Hyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...

Both sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said at least five so...

Ahmedabad has just one restaurant serving Japanese food, Café Formula by Tamura, a joint initiative between Japanese restaurant chain Tamur...

Carlyle private equity backed CLL has transferred its speciality injectables business into a wholly owned subsidiary called CIL.

Shareholders of the company approved the transfer along with all employees, assets and liabilities at a consideration not less than its boo...

"The objective of the buy-back is to return surplus cash to the equity shareholders of the company," Claris said in a filing to the BSE.

A core value of Japanese business is trust. And this is where Daiichi Sankyo’s Ranbaxy problem may start to hurt India-Japan ties.

Claris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...

Ahmedabad-based Claris Lifesciences registered de-growth of 29% in its first quarter ended on 31st March 2013.

The government today said it has approved 12 FDI proposals, including that of pharma firm Claris Otsuka, totalling over Rs 2,609 crore.

Indian shares are expected to trade in a range. Here is a list of ten stocks that are likely to be in action in morning trade today.

Buyout fund Carlyle had shown interest in buying the company and had even valued it at about Rs 3,800 crore.

Claris Lifesciences on Thursday said it will invest Rs 900 crore, which it expects to receive as part of divestment of 80 per cent stake in...

Ahmedabad-based Claris Lifesciences Limited, India executed agreements for a Joint Venture with two Japan-based drug makers Otsuka Pharmace...

Shares of Claris have rallied 165 per cent from the start of the year and are currently trading at their lifetime high.